NANJING, China, June 24 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced the filing of its annual report on Form 20-F for the year ended December 31, 2007 with the Securities and Exchange Commission. The annual report can be accessed on the Company’s investor relations website at http://ir.simcere.com. The Company will provide a hard copy of its audited financial statements for the year ended December 31, 2007 free of charge to its shareholders and ADS holders upon request.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com .
CONTACT: Investor and Media Contact: ir@simcere.com; In Nanjing: Frank
Zhao, Chief Financial Officer of Simcere Pharmaceutical, +86-25-8556-6666
ext 8818, zhaozhigang@simcere.com; or In the United States: Michael Guerin,
+1-212-333-3810, mguerin@brunswickgroup.com, or In Beijing: Kejia Wu,
+86-10-6566-4651, kwu@brunswickgroup.com, or In Hong Kong: Joseph Lo
Chi-Lun, +852-3512-5033, jlo@brunswickgroup.com, all of Brunswick Group,
for Simcere Pharmaceutical Group
Web site: http://www.simcere.com/
http://ir.simcere.com/
